PPARδ as a therapeutic target in metabolic disease
Open accessAbstract
PPAR delta is the only member in the PPAR subfamily of nuclear receptors that is not a target of current drugs. Animal studies demonstrate PPAR delta activation exerts many favorable effects, including reducing weight gain, increasing skeletal muscle metabolic rate and endurance, improving insulin sensitivity and cardiovascular function and suppressing atherogenic inflammation. These activities stem largely from the ability of PPAR delta to control energy balance, reduce fat burden and protect against lipotoxicity caused by ectopic lipid deposition. Therefore, PPAR delta represents a novel therapeutic target and the development of PPAR delta gonists/modulators may be useful for treating the whole spectrum of metabolic syndrome.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PPARd is known for stimulation of fatty acid oxidation in different tissues such as adipose tissue and skeletal muscles.
“In contrast to this assumption, PPARd is known for the stimulation of fatty acid oxidation in different tissues such as adipose tissue and skeletal muscles (Reilly and Lee, 2008).”
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · see citing works
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · see citing works
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690 · see citing works
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546 · see citing works
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296 · see citing works
Self-citationTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832 · see citing works
Etiology of Insulin Resistance
Petersen, K. F., & Shulman, G. I. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.009 · Cited by 825 · cited 1× · see citing works
“believed to be one of the major causes of metabolic diseases [42,43].”
BackgroundBarak, Y., Liao, D., He, W., Ong, E. S., Nelson, M. C., Olefsky, J. M., Boland, R., & Evans, R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012610299 · Cited by 586 · see citing works
Activation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727 · see citing works
Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., & Lee, C.-H. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.002 · Cited by 699 · see citing works
Jung, T. W., Lee, S. H., Kim, H.-C., Bang, J. S., Abd El-Aty, A. M., Hacımüftüoğlu, A., Shin, Y. K., & Jeong, J. H. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0147-5 · Cited by 203 · see citing works
Jung, T. W., Hwang, H.-J., Hong, H. C., Yoo, H. J., Baik, S. H., & Choi, K. M. (2015) · Diabetologia · doi:10.1007/s00125-015-3663-z · Cited by 145 · see citing works
Malik, V. S., Chiuve, S. E., Campos, H., Rimm, E. B., Mozaffarian, D., Hu, F. B., & Sun, Q. (2015) · Circulation · doi:10.1161/circulationaha.114.014911 · Cited by 89 · see citing works
Schubert, M., Becher, S., Wallert, M., Maeß, M. B., Abhari, M., Rennert, K., Mosig, A. S., Große, S., Heller, R., Grün, M., et al. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117887 · Cited by 35 · see citing works
- Authors
- Reilly, S. M., & Lee, C.-H.
- Affiliations
- Harvard University (US)
- Corresponding author
- Lee, Chih-Hao
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2007-11-26
- Volume
- 582
- Issue
- 1
- Pages
- 26-31
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- PMC
- PMC2275052
- OpenAlex
- W2038259293
- Cited by
- 164
- References
- 9
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 14 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 11 · 2015: 9 · 2014: 10 · 2013: 14 · 2012: 8
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- FEBS Letters (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32es007155-24)
- National Institute of Environmental Health Sciences (T32-ES07155, T32-ES007155, T32ES016645)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARδ, metabolic syndrome, therapeutic target, energy balance, insulin sensitivity, skeletal muscle metabolism, endurance, cardiovascular function, lipotoxicity, ectopic fat deposition, weight gain, PPAR agonists
- MeSH terms
- Humans, Metabolic Syndrome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
